Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-0366

Known as: MK 366, MK 0366, MK366 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The in vitro activity of norfloxacin (MK366) against 477 aerobic gram-negative and gram-positive clinical isolates was compared… Expand
  • table 1
  • table 2
Is this relevant?
1983
1983
Norfloxacin is a new orally absorbed quinoline derivative structurally related to nalidixic acid but showing an expanded… Expand
Is this relevant?
1983
1983
Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram… Expand
Is this relevant?
1983
1983
A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents… Expand
  • table 1
Is this relevant?
1983
1983
Norfloxacin (MK0366) displayed appreciable activity against the great majority of Gram-negative and Gram-positive bacteria. The… Expand
Is this relevant?
1982
1982
The in vitro activity of norfloxacin (MK-0366) compared with that of beta-lactam antibiotics and, where appropriate of gentamicin… Expand
Is this relevant?
1982
1982
A high-performance liquid chromatographic method for the analysis of norfloxacin (MK-366) [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7… Expand
Is this relevant?
1982
1982
MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia… Expand
  • figure 1
Is this relevant?
1982
1982
The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid… Expand
  • table 1
Is this relevant?
1981
1981
The in vitro activity of a new ora antimicrobial agent, Mk-0366 (AM-715), was compared with those of rosoxacin, ampicillin… Expand
Is this relevant?